Interleukin Inhibitors Industry

According to a recent report by Grand View Research, Inc., the global interleukin inhibitors market is projected to reach a value of USD 72.2 billion by 2030. The market is expected to grow at a strong compound annual growth rate (CAGR) of 17.3% between 2025 and 2030. This significant growth is primarily attributed to the robust pipeline of interleukin inhibitors, which includes several promising drug candidates currently in late-stage clinical development and nearing market launch.

The therapeutic landscape for interleukin inhibitors is becoming increasingly dynamic and competitive, as pharmaceutical companies are conducting head-to-head clinical trials to directly compare the safety, efficacy, and tolerability of different treatment options. A notable example includes UCB’s investigational drug bimekizumab, which is currently being tested in three comparative trials: BE SURE (against Humira), BE VIVID (against Stelara), and BE RADIANT (against Cosentyx). All three studies are focused on evaluating bimekizumab for the treatment of plaque psoriasis.

In addition, a surge in investments for clinical research and growing strategic collaborations between pharmaceutical firms and academic or healthcare research institutions are playing a pivotal role in the advancement of novel interleukin-targeting therapies. For example, Genentech, a subsidiary of F. Hoffmann-La Roche Ltd., has partnered with Massachusetts General Hospital to further develop Actemra (tocilizumab) for the treatment of giant cell arteritis, a chronic inflammatory disease of the blood vessels.

The market is also being driven by rising public awareness about autoimmune diseases and the growing availability of treatment options. Increased efforts by advocacy groups and non-profit organizations to educate patients are helping fuel demand for interleukin inhibitors. For instance, Arthritis Ireland launched a public awareness campaign focused on rheumatoid arthritis, aiming to inform people about early symptoms, diagnostic methods, and available therapies. Similarly, the European Federation of Crohn's & Ulcerative Colitis Association continues to implement various initiatives aimed at raising awareness among individuals suffering from Inflammatory Bowel Disease (IBD), encouraging timely diagnosis and appropriate treatment.

These combined factors—ranging from clinical innovation and corporate partnerships to patient advocacy and education—are expected to significantly bolster the growth of the interleukin inhibitors market over the forecast period.

Curious about the Interleukin Inhibitors Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Interleukin Inhibitors Market Segments Highlights:

  • By application, the psoriatic segment leading the market and accounted for a share of 37.0% in 2024
  • In 2024, IL-23 inhibitors led the market with a revenue share of 27.5%, due to their efficacy in treating autoimmune diseases, such as psoriasis and IBD.
  • By type, IL-17 inhibitors are expected to witness a significant CAGR of 16.1% over the forecast period.
  • Asia Pacific is expected to exhibit the fastest regional growth over the forecast period, fueled by enhanced healthcare infrastructure and growing disposable incomes.
  • Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.

Interleukin Inhibitors Market Report Segmentation

Grand View Research has segmented the global interleukin inhibitors market based on type, route of administration, application, end-use, and region:

Interleukin Inhibitor Type Outlook (Revenue, USD Million, 2018 - 2030)

  • IL-1 Inhibitors
  • IL-2 Inhibitors
  • IL-5 Inhibitors
  • IL-6 Inhibitors
  • IL-17 Inhibitors
  • IL-23 Inhibitors
  • Others

Interleukin Inhibitor Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Subcutaneous (SC)
  • Intravenous (IV)

Interleukin Inhibitor Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Rheumatoid Arthritis
  • Psoriasis
  • Inflammatory Bowel Disease (IBD)
  • Asthma
  • Others

Interleukin Inhibitor End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals
  • Specialty Clinics
  • Others

Interleukin Inhibitor Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Key Interleukin Inhibitors Company Insights

  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Hoffmann-La Roche Ltd
  • AstraZeneca
  • Bausch Health Companies Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd

Order a free sample PDF of the Interleukin Inhibitors Market Intelligence Study, published by Grand View Research.